We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Clinical Validation Bolsters Liquid Biopsy Evidence Base

By LabMedica International staff writers
Posted on 15 May 2019
Non–small-cell lung cancer (NSCLC) accounts for more than 85% of lung cancer – the majority of patients who present have advanced-stage disease and are treated with systemic therapies. More...
Great strides have been made in the development of therapies for such patients, including targeted therapies and immunotherapy.

Plasma-based assays for molecular profiling of tumor mutations through circulating tumor DNA (ctDNA) offer the potential to overcome difficulties associated with tissue-based comprehensive genomic profiling (CGP). These less-invasive liquid biopsies are now entering routine clinical practice and National Comprehensive Cancer Network guidelines are recommending their use in patients with NSCLC when tissue biopsy is not available.

A large team of scientists led by those at the Washington University School of Medicine (St. Louis, MO, USA) prospectively recruited a total of 264 patients with untreated advanced NSCLC were, and their plasma was analyzed using a ctDNA NGS assay for detection of genomic alterations in 36 commonly mutated genes. Tumor tissue was available in 178 patients for molecular profiling for comparison with plasma profiling. The remaining 86 patients were included to compare ctDNA profiles in patients with and without tissue for profiling.

Blood was collected and after plasma extraction, plasma was stored at -80 °C. DNA was extracted from plasma using the QIAamp Circulating Nucleic Acid kit. After quality control, sequencing libraries were prepared using a two-step amplification process, and libraries were sequenced on a NextSEquation 500. Sequencing data were analyzed using the InVisionFirst-Lung assay and analytical pipeline to identify genomic alterations.

The authors reported that Inivata's InVisionFirst-Lung demonstrated "excellent concordance" with tissue profiling, with a high level of sensitivity and specificity. Notably, the liquid biopsy test was able to detect 26% more actionable alterations than standard-of-care tissue testing, at least in part because it worked more often than tissue testing. When all the data came in, at least some tissue sequencing was available for 178 of the patients in the two cohorts. But only 95 of these cases had comprehensive tissue sequencing covering all of what the study defined as crucial actionable genes. The other 86 patients had results only from InVisionFirst-Lung. Across the total enrolled population, investigators found that InVisionFirst-Lung detected "actionable alterations" in 48 individuals, compared to only 38 with tissue testing, representing a 26% improvement.

Ramaswamy Govindan, MD, professor of medicine and the study's senior author, said, “The detection of an increased percentage of patients with actionable mutations using liquid biopsy demonstrates how this technology can ensure more NSCLC patients can be treated with the appropriate therapy, improving their chances of durable response and survival.” The study was published on April 25, 2019, in the journal JCO Precision Oncology.

Related Links:
Washington University School of Medicine


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.